Compounded Sermorelin Should Not Be Used as a Substitute for FDA-Approved Somatropin in Growth Hormone Deficiency
No, compounded sermorelin products should not be used off-label for patients with documented growth hormone deficiency (GHD), even when FDA-approved recombinant somatropin is not accessible. The standard of care for adult GHD is FDA-approved recombinant human growth hormone (somatropin), and there is no evidence supporting compounded sermorelin as an equivalent alternative 1.
Why Somatropin is the Only Appropriate Treatment
The Endocrine Society Clinical Practice Guidelines explicitly state that biosynthetic human growth hormone (somatropin) is the approved treatment for adult GHD 2. FDA-approved somatropin products like Nutropin AQ are specifically indicated for treatment of adults with either childhood-onset or adult-onset GHD 1. These products have undergone rigorous safety and efficacy testing, proper labeling with warnings, and quality control standards 1.
The Problem with Compounded Sermorelin
Lack of FDA Approval and Safety Data
- Compounded bioidentical hormone therapies (including sermorelin) do not have proper FDA labeling and warnings 3
- The 2013 Drug Quality and Security Act was passed specifically due to concerns about widespread use of non-FDA-approved compounded products, particularly after 64 patient deaths from contaminated compounded medications 3
- Compounded products lack the safety, efficacy, and quality control data required for FDA approval 3
Inferior Clinical Efficacy
Research directly comparing sermorelin to somatropin demonstrates that sermorelin is substantially less effective:
- In children with GHD, sermorelin given as continuous subcutaneous infusion or 3 divided doses produced less height velocity increase than once-daily somatropin at the same 30 mcg/kg/day dose 4
- A study of 7 children with hypothalamic GHD showed that 5 of 7 patients did not improve their growth rate with GHRH therapy, but all patients showed catch-up growth when switched to recombinant human GH 5
- Even when sermorelin showed some effect, it required twice-daily dosing and produced inconsistent results 5
Mechanism Limitations
Sermorelin (a growth hormone-releasing hormone analog) works by stimulating the pituitary to release endogenous GH 4. This approach has fundamental limitations:
- It only works if the pituitary gland is capable of responding
- It cannot provide consistent GH levels throughout the day
- It is ineffective in patients with pituitary damage or structural lesions causing GHD
What to Do When Somatropin Access is Limited
If a patient truly cannot access FDA-approved somatropin due to insurance, cost, or availability issues:
Exhaust all options for obtaining FDA-approved somatropin first:
- Patient assistance programs from manufacturers
- Prior authorization appeals with detailed documentation of GHD
- Alternative FDA-approved somatropin formulations
- Specialty pharmacy networks
Document the specific barriers preventing access to FDA-approved therapy in the medical record
Do not substitute with compounded sermorelin as it is not an equivalent therapy and lacks evidence for efficacy in adult GHD
Consider whether treatment can be safely deferred while working to obtain proper medication, weighing the risks of untreated GHD against using an unproven compounded product
Critical Safety Considerations
The FDA label for somatropin includes important contraindications that must be evaluated before any GH-related therapy 1:
- Active malignancy
- Acute critical illness
- Active proliferative or severe non-proliferative diabetic retinopathy
- Known hypersensitivity to somatropin
Proper diagnosis of GHD must be confirmed with appropriate stimulation testing before considering any treatment 2, 6. The Endocrine Society recommends GH stimulation tests for diagnosis, with consideration of age, sex, and BMI factors that affect GH response 6.
The Bottom Line
Using compounded sermorelin as an off-label substitute for FDA-approved somatropin represents substandard care that exposes patients to:
- Products without proven efficacy for adult GHD
- Lack of quality control and safety oversight
- Potential contamination risks inherent to compounded products
- Inadequate treatment of a documented hormone deficiency
The appropriate course of action is to pursue all available avenues to obtain FDA-approved somatropin rather than substituting an inferior, unproven compounded product 2, 1, 3.